Home » Stocks » ADIL

Adial Pharmaceuticals, Inc. (ADIL)

Stock Price: $1.74 USD -0.05 (-2.79%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed
After-hours: $1.73 -0.01 (-0.58%) Oct 30, 7:56 PM

Stock Price Chart

Key Info

Market Cap 23.60M
Revenue (ttm) n/a
Net Income (ttm) -7.86M
Shares Out 13.56M
EPS (ttm) -0.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 30, 2020
Last Price $1.74
Previous Close $1.79
Change ($) -0.05
Change (%) -2.79%
Day's Open 1.79
Day's Range 1.69 - 1.80
Day's Volume 338,006
52-Week Range 1.00 - 4.00

More Stats

Market Cap 23.60M
Enterprise Value 14.97M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 13.56M
Float 10.99M
EPS (basic) -0.74
EPS (diluted) -0.74
FCF / Share -0.56
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 615,457
Short Ratio 0.10
Short % of Float 5.60%
Beta 0.45
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 2.71
Revenue n/a
Operating Income -7.96M
Net Income -7.86M
Free Cash Flow -6.29M
Net Cash 8.62M
Net Cash / Share 0.64
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -49.32%
ROE -83.40%
ROIC -2,403.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

Current: $1.74
Target: 5.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-8.24-6.99-1.00-0.41
Net Income-8.59-11.63-1.14-0.42
Shares Outstanding9.854.763.263.26
Earnings Per Share-0.87-2.44-0.35-0.13
Operating Cash Flow-6.34-2.50-0.49-0.27
Free Cash Flow-6.34-2.50-0.49-0.27
Cash & Equivalents6.783.870.020.12
Total Debt--0.690.23
Net Cash / Debt6.783.87-0.67-0.11
Book Value7.144.44-1.00-0.10
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Adial Pharmaceuticals, Inc.
Country United States
Employees 3
CEO William B. Stilley

Stock Information

Ticker Symbol ADIL
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ADIL
IPO Date July 30, 2018


Adial Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. The company was founded in 2010 and is based in Charlottesville, Virginia.